Proteomics Leadership Positioned as a leader in proteomics and high-resolution separation science, MOBILion is expanding with a next-generation proteomics platform and MOBIE deployments. This creates opportunities to upgrade existing accounts, win new ones, and offer related instruments, consumables, services, and training to biopharma and CROs focused on biologics characterization, biomarker discovery, and diagnostics.

Software Upsell EyeOn 2.3 and MOBIE software capabilities offer an avenue to upsell advanced data processing, higher sensitivity workflows, and faster analysis. There is potential to sell software licenses, data analytics services, and integration with customers' lab IT stacks such as LIMS, Jira, and Confluence, or automation pipelines.

Partnerships & Advisory Launching a Proteomics Advisory Board signals a collaborative ecosystem strategy. Target pharma and biotech labs, academia, and CROs for joint studies, co-development, and co-marketing efforts; leverage HUPO and ASMS activity to build partner programs and publish case studies.

Mid-market Focus With a small-to-mid sized team and revenue in the mid-range, MOBILion serves growing biotech labs and CROs that require scalable, high-performance proteomics solutions. Propose managed services, installation support, training, and on-site demonstrations at industry events to convert trials into long-term contracts.

Competitive Position MOBILion competes with large instrument companies such as Bruker, Waters, PerkinElmer and SCIEX; emphasize speed and sensitivity advantages to win opportunities in biologics characterization and diagnostic development. Target labs upgrading from older platforms and pharma R&D groups seeking faster validation of biomarkers.